Sucampo Announces First Quarter 2015 Earnings Call
April 22 2015 - 6:45AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will host its
first quarter 2015 financial results teleconference and webcast at
8:30 a.m. Eastern on Wednesday, May 6, 2015. The press release
announcing the financial results and operating highlights is
expected to be released before the opening of capital markets that
day.
Individuals interested in accessing the live audio webcast of
the teleconference may do so at
http://www.sucampo.com/investors/events-presentations/ and should
log on 10 to 15 minutes before the teleconference begins to
download any software required. Presentation slides will be
available via the webcast link. A replay of the webcast will also
be available on Sucampo's website for several days after the live
event. Alternatively, individuals may dial 877-280-4960 (domestic)
or 857-244-7317 (international) and use passcode 37225960. A replay
of the teleconference will be available by dialing 888-286-8010
(domestic) or 617-801-6888 (international), passcode 47934985,
approximately two hours after the teleconference concludes. The
archive of the teleconference will be available for 30 days.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and
commercialization of medicines that meet major unmet medical needs
of patients worldwide. Sucampo has one marketed product – AMITIZA®
– and a pipeline of drug candidates in clinical development. A
global company, Sucampo is headquartered in Bethesda, Maryland, and
has operations in Japan, Switzerland and the United Kingdom. For
more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; the ability of Sucampo to develop,
commercialize or license existing pipeline products or compounds or
license or acquire non-prostone products or drug candidates;
Sucampo's ability to accurately predict future market conditions;
dependence on the effectiveness of Sucampo's patents and other
protections for innovative products; the risk of new and changing
regulation and health policies in the U.S. and internationally; the
effects of competitive products on Sucampo's products; and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on March
9, 2015 as well as its filings with the Securities and Exchange
Commission on Form 8-K, which Sucampo incorporates by
reference.
CONTACT: Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Communications
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024